Oncology News | pharmaphorum

Tuesday 4 August 2026

News

News

nektar_sign-san_francisco

Nektar, BioMarin, and Alnylam top list of biotech M&A target...

With Takeda’s £46 billion acquisition of Shire, it’s been a busy year for pharma M&A – and according to analysts Datamonitor, the specialist biotechs Nektar, BioMarin and Alnylam are th

News

Known as Cabometyx in the US, the drug is licensed by Ipsen from Exelixis

EU approves Ipsen's Cabometyx in first line kidney cancer

Drug looks set to become core part of Ipsen's cancer offering

News

AstraZeneca Amenities Building - Mississauga - Sept 2005
Non exclusive, unlimited time license for print & web to WZMH Architects

AstraZeneca feels pain as sales slump continues

First quarter results from AstraZeneca have disappointed investors, sending shares down on the London Stock Exchange, as the UK firm continued to feel the effects of patent losses on key dr

News

Medical vials and Syringe, Isolated on Blue background

Moderna and Merck expand partnership to develop new cancer v...

Moderna and Merck & Co have expanded their partnership to develop and commercialise novel personalised messenger RNA (mRNA) cancer vaccines.

News

lillyhq

Lilly buys cancer biotech ARMO for $1.6bn

Lilly adds pancreatic cancer drug to pipeline

News

NHS cuts clinical trial bureaucracy

NHS chiefs have introduced new arrangements to fast track clinical trials and improve patients’ access to cutting-edge therapies.